MSD is looking for a digital health solution to empower oncologists by keeping them updated in their field

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The solution should consider several channels (web, app, email newsletter, social media, etc) and adapt to the preferences to each user, so they are motivated to access the content regularly over time.

As a leading pharmaceutical company, MSD is aware of the need to incorporate open Innovation for better healthcare. The best ideas may not always pop up where challenges are identified. That is why MSD wants to support and partner with external talent to collaboratively develop competitive solutions following a win-win approach.

The Lebanon-College Challenge: Empowering oncologists to save lives

Lebanese oncologists face challenges to stay updated with their practice, mainly due to time constraints. The vast amount of data that is being published in the field, and their clinical and academic responsibilities, are the main reasons for these time limitations.

MSD Lebanon aims to enter into a co-creation process with an external partner that provides the service that includes the use of a digital solution that helps oncologists to stay updated with relevant clinical content about cancer updates. The applicant must be able to provide both the content and the technological platform to deliver it to the Lebanese doctors.

Expected functionality and characteristics: The applicant must be able to manage the whole life-cycle of the content - identification, selection, tagging, uploading. Besides, the digital solution must be: user-friendly, trustable, multi-channel, multi-content, customizable, adherent, measurable, restricted to Lebanese oncologists, provide printed copies of content, comply with security and privacy.

The schedule

The process is done in five steps:
1. Solutions submitted before 21st December 2018 are reviewed by the MSD team.
2. Up to four finalists will be announced on 21st January 2019.
3. Finalists receive mentorship to improve their initial proposal.
4. Finalists pitch their proposal at the Selection Event in Beirut on 5th March 2019.
5. Winning proposal will be co-created and rolled-out in the local market with MSD team support.

The prizes

The winner will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market (Lebanon).
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

Each finalist will receive €400 to cover travel expenses. It is compulsory to physically attend the event to become a winner (no remote presentations).

Who can apply? Any company that is incorporated in any country. Consortia are permitted. Any technology is welcome with the exception of chatbots. The working language will be English.

For detailed information about the initiative including challenges and process, please visit:
http://www.msdinnovationfactory.com

About the MSD Innovation Factory and MEA Region

Since 2016 the MSD Innovation Factory has been established as an open innovation vehicle for the MEA Region with the main objective of finding co-creation opportunities with external partners to deliver sustainable solutions for our patients and customers.

With a footprint that spans across 2 continents and serving a population of close to 1.7 billion people, MEA is one of the most diverse regions within MSD. Our region is a true melting pot, possessing a rich mix of cultures, ethnicities and backgrounds that are fundamental to our company's success. As we aspire to improve health and wellness across MEA, we apply the combined knowledge, skills and experiences of thousands of employees in the Human Health, Animal Health, Manufacturing and Research divisions.

Our researchers are at the forefront of exploring new ways to address health challenges, with clinical trials running in several countries across the region. High disease burdens across the region for Cancer, Hepatitis C and Diabetes among many others, keep us conscious of our responsibility, and committed to our mission to ensure that the medicines and vaccines we invent will lead to better health for society for generations to come.

Most Popular Now

Favipiravir flu drug 'clearly effective' in treati…

According to the multiple news articles the drug favipiravir (sold under the brand name Avigan), developed by Fujifilm Toyama Chemical, had produced encouraging outcomes ...

New kind of CRISPR technology to target RNA, inclu…

CRISPR-based genetic screens have helped scientists identify genes that are key players in sickle-cell anemia, cancer immunotherapy, lung cancer metastasis, and many othe...

COVID-19: The immune system can fight back

Melbourne researchers have mapped immune responses from one of Australia's first novel coronavirus (COVID-19) patients, showing the body's ability to fight the virus and ...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Understanding how COVID-19 affects children vital …

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandem...

Free EDC software for non-profit COVID-19 related …

Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies. The platform is made available for t...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

Novartis announces broad range of initiatives to r…

Novartis today announced a broad set of measures to support the global response to the COVID-19 pandemic. These measures include the creation of a global fund to support ...